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Lymphatic metastasis in papillary thyroid cancer (PTC) is eminent; however, the extent of central compartment lymph nodes
dissection (CCD) is controversial and requires the knowledge of pattern and risk factors for central compartment lymph nodes
metastasis (CCM). We did a prospective study of 47 cases with PTC who underwent total thyroidectomy (TT) with CCD
with/withoutlaterallymphnodesdissection(LND).ClinicopathologicalproﬁleincludingCCMasipsilateralandcontralateralwas
documented. On histopathology, the mean tumour size was 3.57 ± 2.42cm 59.6% had CCM, which was bilateral in the majority
(60.72%). The tumour-size was the most important predictor for lymph nodes metastasis-(P = 0.018) whereas multicentricity-
(P = 0.002) and ipsilateral CCM-(P = 0.001) were the predictors for contralateral CCM. The long-term morbidity of CCD done
in primary setting is comparable with TT-alone. Bilateral CCD should be done with thyroidectomy in PTC, otherwise the risk of
residual diseases and subsequent recurrence is high. The long-term morbidity is comparable in experienced hands.
1.Introduction
Papillary thyroid cancer (PTC) is the most common thyroid
malignancy with the predilection for lymphatic spread [1].
Like any other head and neck malignancy, the lymphatic
spread of PTC is supposed to follow a sequential pattern
with the central compartment or level VI lymph nodes being
ﬁrst to involve [2–4], which besides containing the pre-
and paratracheal lymph nodes, also contains the parathyroid
glands and recurrent laryngeal nerves on either side, which
are prone to injury while dissecting the central compartment
lymph nodes [4]. The central compartment lymph nodes
dissection (CCD) in PTC has the advantages of complete
clearance of the disease, thereby reducing the chances of
recurrence and the subsequent morbidity of reoperation,
also it provides the nodes for exact nodal staging to plan
furtheradjuvanttherapyandprognosticatethepatient[5,6].
However, it is associated with increased risk of hypoparathy-
roidism and recurrent laryngeal nerve palsy [7]. Therefore
for high-risk with clinically involved nodes the routine
CCD is acceptable; however, it is controversial for low-risk,
clinically uninvolved nodes [8], with some advocating for [9,
10] and some against [11] routine bilateral clearance while a
third group of surgeons adopted a midway, by dissecting the
ipsilateral side only, thus sparing the contralateral parathy-
roid glands and recurrent laryngeal nerve [12–14]. The
extent of lymphadenectomy in PTC is still controversial and
requires the knowledge of pattern of central compartment
lymph nodes metastasis. Therefore, we aim our study to
ﬁnd out the pattern and risk factors of central compartment
lymph node metastasis (CCM), and the morbidity of CCD.
2.MaterialandMethod
We did a prospective study of all patients with papillary
thyroid cancer, who underwent total thyroidectomy (TT)
with CCD as a primary surgery from September 2008 till
November 2010 at Department of Endocrine Surgery, Sanjay
GandhiPostgraduateInstituteofMedicalSciences,Lucknow,
India. The study was approved by department review board,2 Journal of Thyroid Research
Table 1: Demographic proﬁle of the patients; n = 47 (% age).
Mean age ± SD (range) years 35.79 ± 12.65
(9–69)
Age group
(i) ≤45 years 40 (85.1)
(ii) >45 years 7 (14.9)
Sex (male:female) 31:16
Clinical presentation
(i) Solitary thyroid nodule 42 (89.4)
(ii) Multinodular goiter (MNG) 2 (4.3)
(iii) MNG with dominant nodule 3 (6.4)
Occult papillary thyroid cancer 4 (8.5
Functional status
(i) Euthyroid 41 (87.2)
(ii) Hypothyroid 6 (12.8)
Clinical nodal staging (TNM-classiﬁcation)
(i) cN0 29 (61.7)
(ii) cN1b 18 (38.3)
Surgical procedure
(i) TT + B/L CCD 28 (59.6)
(ii) TT + B/L CCD + U/L MRND 13 (27.7)
(iii) TT + B/L CCD + B/L MRND 4 (8.5)
( i v )T T+U / LC C D+U / LM R N D 2( 4 . 3 )
written and informed consent was taken from the patients,
as per the department protocol. Preoperatively, besides a
detailedhistoryandexamination,wedidtheultrasoundneck
and ﬁne-needle aspiration cytology of the thyroid nodules
and any suspicious cervical lymph nodes, and a preoperative
clinical staging based on 6th AJCC [15] was done. Final
staging was done after the histopathology report (p-TNM).
We excluded patients with missed initial diagnosis of PTC
who did not undergo CCD, reoperative surgeries (like com-
pletion thyroidectomy and locoregional recurrence), and
concomitant hyperparathyroidism. “Central compartment”
isdeﬁnedasanareathatisbounded superiorlybythehypoid
bone, inferiorly by the innominate vein, and on either side
by the carotid sheaths [16]. We did the thyroidectomy with
standard technique of capsular dissection. The thyroid along
with the central compartment lymph nodes was removed en
bloc in all the cases and the ﬁbrofatty tissue was divided in
midline and sampled as right and left paratracheal lymph
nodes [9]. Formal lateral lymph nodes dissection involving
the level II, III, and IV were done in patients with proven
lateral lymph nodes metastasis. We routinely identiﬁed
all the parathyroid glands, external branch of superior
laryngeal nerves and recurrent laryngeal nerves and tried to
save them in situ. Any at-risk gland was autotransplanted
in sternocleidomastoid muscle. We grossed the specimen
in operation theatre and in pathology department under
supervision of a single pathologist (SJ) involved in the
study. Along with detailed grossing of thyroid, the individual
lymph nodes from lymph nodes basins were also separated,
counted, and embedded. Following processing 3µm thick
sections were examined under microscope. For the purpose
of description, the term “ipsilateral” was designated to the
side with largest tumor size [9]. The complications were
assessed in immediate postoperative period and 6 months
following surgery and compared with a group of benign
thyroid disorders, who underwent total thyroidectomy alone
in primary setting during the same period. “Hypocalcemia”
was deﬁned as corrected serum calcium ≤8mg/dLwithor
without clinical features of hypocalcemia. Any patient with
signiﬁcant postoperative hoarseness underwent vocal cord
examinationbyindirectlaryngoscopytodocumentrecurrent
laryngeal nerve (RLN) palsy. Hypocalcemia and RLN palsy
are termed as temporary when it is resolved within 6 months
of surgery. Patients with hypocalcemia were managed with
oral/parenteral calcium and vitamin D, as per department
protocol [17–19]. Following 6 months after surgery we did
the serum parathyroid hormone analysis in any patient
with persistently low serum calcium and requiring calcium
and vitamin D support, thereby documenting permanent
hypoparathyroidism. Similarly in all the patients with RLN
palsy, vocal cord assessment was done at 6 months following
surgery to document permanent RLN paralysis.
2.1. Statistical Analysis. Analysis was done by the SPSS 17.
We used frequency, percentages, mean ± standard deviation,
range, Student’s t-test, chi-square test, and Fischer exact test,
wherever applicable. Univariate and multivariate analysis is
done using logistic regression.
3. Results
As shown in Table 1 at the end of study 47 cases were
included. The mean age was 35.79 ± 12.65 years with female
preponderance (31:16). Majority were presented with soli-
tary thyroid nodule (42/47). 4/47 cases presented with lateral
l y m p hn o d em e t a s t a s i sw i t ho c c u l tP T C .M a j o r i t yw e r e
node negative (29/47) on clinical examination and imaging.
CCD was done in all cases. 19/47 patients underwent lateral
lymph nodes dissection also Table 2. Histopathology of
thyroid showed, mean tumor size 3.57 ± 2.42. Classical
variant was present in 35/47, other variants being follicular,
oncocytic variant [20], and tall cell. Tumor was bilateral in
9/47 cases, multicentric in 18/47, and with extra thyroidal
extension in 13/47 cases. Overall lymph node metastasis
was present in 30/47. Out of which 28/47 cases had CCM.
Majority had bilateral central compartment lymph nodes
metastasis (17/47), with isolated ipsilateral CCM in 9/47
and isolated contralateral CCM in 2/47. All patients with
lateral lymph nodes dissection (19/47) had metastatic lateral
lymph nodes on histopathology. Isolated ipsilateral LLNM
was present in 15/19, bilateral LLNM in 3/19, and isolated
contralateral LLNM in 1/19 cases. Skip lateral metastasis,
skipping the central compartment was present in 2/19 and
skip contralateral CCM, skipping the ipsilateral CCLN was
present in 2/45 cases. At the end of study, 3 cases were
upstaged from clinically node negative to histopathologically
provennodepositive(2caseswithCCMandonepatientwith
CCM and lateral LNM). The univariate analysis was done to
ﬁndouttheassociationofvariousknownriskfactorslikeage,Journal of Thyroid Research 3
Table 2: Histopathological features; n = 47 (% age).
Thyroid
Mean tumor size (cm) ± SD (range) 3.57 ± 2.42
(0.3–12)
Tumor staging
(i) T1 4 (8.5)
(ii) T2 19 (40.4)
(iii) T3 11 (23.4)
(iv) T4 13 (27.7)
Papillary microcarcinoma 8 (17)
PTC subtypes
(i) Classical variant (CV) 35 (74.5)
(ii) Follicular variant (FV) 8 (17)
(iii) Oncocytic variant (OV) [20]1 ( 2 . 1 )
(iv) Tall cell variant (TCV) 3 (6.4)
Laterality
(i) Right side 29 (61.7)
(ii) Left side 18 (38.3)
Multicentricity 18 (38.3)
Bilaterality 9 (19.1)
Extrathyroidal extension 13 (27.7)
Lymph nodes
Overall lymph nodes metastasis 30 (63.8)
Overall central compartment lymph nodes
metastasis (CCM) 28 (59.6)
(i) Bilateral CCM 17 (60.72)
(ii) Isolated ipsilateral CCM 9 (32.14)
(iii) Isolated contralateral CCM 2 (7.14)
Overall lateral compartment lymph nodes
metastasis (LLNM; n = 19) 19 (100)
(i) Ipsilateral LLNM 15 (78.95)
(ii) Bilateral LLNM 3 (15.8)
(iii) Contralateral LLNM 1 (5.3)
Final pathological nodal staging
(TNM-classiﬁcation)
(i) pN0 25 (53.2)
(ii) pN1a 3 (6.4)
(iii) pN1b 19 (40.4)
Skip lateral metastasis (n = 19) 2 (10.5)
Skip contralateral central lymph node metastasis
(n = 47) 2 (4.3)
age group (≤45 years), sex, tumor size, pathological tumor
staging, tumor subtypes, multicentricity, bilaterality, and
extrathyroidal extension (Table 3). We did ﬁnd a signiﬁcant
association of tumor size with the CCM (4.2 ± 2.45 versus
2.58 ± 2.02; P = 0.018). Similarly, ipsilateral CCM was
signiﬁcantly associated with primary tumor size (4.4 ± 2.4
versus 2.5 ± 2.0; P = 0.013), and contralateral CCM was
signiﬁcantly associated with multicentricity (36.8% versus
18.5%;P = 0.003)andipsilateralCCM(89.5%versus33.3%;
P = 0.000). Multivariate analysis showed ipsilateral CCM
metastasis as a signiﬁcant risk factor for contralateral CCM
(P = 0.02). In our series, 42 patients initially presented
with solitary thyroid nodule conﬁned to one lobe only, but
on ﬁnal histopathology, 8/42 were found to have tumor
foci in both the lobes (bilateral tumors) and 16/42 was
multicentric. Two patients in our series had skip metastasis
to contralateral CCM, skipping the ipsilateral CCM, one
of them was a 40-year-old male, who presented with right
lateral lymph nodes metastasis with occult PTC, underwent
TTwithCCDwithrightMRND,andonﬁnalhistopathology
was detected to have 0.5cm tumor in right lobe thyroid
with multicentricity and bilaterality; second patient, was
a 44-year-old male with clinically evident solitary thyroid
nodule with absent nodes, underwent TT with CCD, and
on histopathology was found to have 4cm tumor with
no evidence of multicentricity and normal opposite lobe.
Similarly,forskiplateralmetastasisthatisskippingtheCCM,
out of two patients, one was a 33-year-old male with lateral
lymph nodes metastasis with occult PTC, histopathology
showed a 0.4cm tumor, with multicentricity with normal
opposite lobe; thesecondpatient wasa62-year-old lady,who
presented with solitary thyroid nodule with lateral lymph
nodes metastasis, the histopathology again revealed a 0.3cm
tumor with no multicentricity and normal opposite lobe;
however, the extrathyroidal extension was present. All the
above-mentioned cases had classical variant of PTC. All
47 cases underwent whole-body radioactive iodine scan 4
to 6 weeks following thyroxin withdrawal, and radioactive
remnant ablation was done in 41/47 patients. All patients
received suppressive L-thyroxin therapy. The morbidity was
compared with age- and sex-matched group of benign
thyroid disorders operated during the same period that
underwent total thyroidectomy alone (Table 4). In our
series, though the rate of inadvertent parathyroidectomy,
temporary hypocalcaemia, and temporary RLN palsy was
signiﬁcantly high in group with CCD (P<0.05), the
long-term morbidity, that is, rate of permanent RLN palsy
and hypoparathyroidism was comparable to those with total
thyroidectomy alone.
4. Discussion
PTC has propensity for lymphatic spread [1]. The metas-
tasis is found in 20–50% of lymph nodes examined by
conventional pathologic examination whereas the rate of
micrometastasis has been found to be much higher in
clinically node negative-cases [21]. The lymph node metas-
tasis in papillary thyroid cancer has been found to have
signiﬁcant impact on disease-free and overall survival of
patients [22, 23]. Giles et al. [24] in their retrospective
series of 343 patients with thyroidectomy but without CCD
found a locoregional recurrence rate of 6% with a median
followup of 9 ± 4 years, where central compartment lymph
nodes were involved in 6 recurrent cases. Similarly, Moo
et al. [5], in their series, during a mean followup of
3.1 years, reported increased locoregional recurrences in
the group undergoing total thyroidectomy alone (16.7%)
compared to those with prophylactic central lymph nodes
dissection (4.4%). Similarly, Ito et al. [25] reported 10-year4 Journal of Thyroid Research
Table 3: Univariate analysis of central compartment lymph nodes metastasis (CCM), ipsilateral CCM and contralateral CCM with known
risk factors.
CCM Ipsilateral CCM Contralateral CCM
Present
n = 28
Absent
n = 19 P value Present
n = 26
Absent
n = 21 P value Present
n = 19
Absent
n = 28 P value
Age (years) 34.96 ± 14.41 37 ± 9.74 0.594 34.42 ± 14.83 37.48 ± 9.38 0.410 34.68 ± 15.77 36.67 ± 11.03 0.602
Age group
≤45 years 24 16 1.000 22 18 1.000 16 23 0.928
>45 years 4 3 4 3 3 4
Sex
Male 9 7 0.763 76 9 0.355 7 8 0.608
Female 19 12 19 12 12 19
Tumor size (cm) 4.2 ± 2.45 2.58 ± 2.02 0.018∗ 4.4 ± 2.4 2.5 ± 2.0 0.013∗ 4.02 ± 2.23 3.38 ± 2.5 0.378
Tumor staging
T 1 22 13 21
T2 8 11 0.326 8 11 0.760 5 14 0.324
T 3 83 83 56
T4 10 3 9 4 7 6
Tumor subtype
Classical
variant 22 13 20 15 14 20
Follicular
variant 3 5 0.580 3 5 0.619 2 6 0.434
Oncocytic
variant 10 10 10
Tall cell variant 2 1 2 1 2 1
Multicentricity 13 5 0.169 12 6 0.245 12 5 0.002∗
Bilaterality 6 3 0.631 5 4 1.000 6 3 0.085
Extrathyroidal
extension 10 3 0.144 10 3 0.102 7 5 0.170
Ipsilateral CCM — — — — — — 17 9 0.001∗
Table 4: Comparison of morbidity following total thyroidectomy
withCCD(n = 47);withtotalthyroidectomyalone(benignthyroid
disorders; n = 130).
Total
thyroidectomy
with CCD;
n = 47
(% age)
Total
thyroidectomy
alone; n = 130
(% age)
P value
Inadvertent
parathyroidectomy 13 (27.7) 0
Temporary
hypocalcemia 41 (87.2) 67 (51.5) 0.000∗
Temporary RLN palsy 8 (17) 9 (6.9) 0.044∗
Permanent
hypoparathyroidism 1 (2.1) 3 (2.3) 0.458
Permanent RLN palsy 1 (2.1) 1 (0.8) 0.419
disease-free survival (DFS) of 97% with elective lymph
nodes dissection in low- risk PTC even without radio-iodine
treatment. On the other hand Rosenbaum and McHenry
[7], reported, no signiﬁcantly reduced recurrence rate with
central neck dissection, but an increased risk of temporary
hypocalcemia, compared with no central cervical lymph
nodes dissection group. The rationale behind the routine
dissection of central compartment lymph nodes in preop-
eratively diagnosed cases of PTC with clinically uninvolved
lymph nodes is manifold; ﬁrst, the PTC has the tendency
for lymphatic spread, which tends to follow a sequential
patternwithipsilateralparatrachealfollowedbycontralateral
paratracheal and ipsilateral lateral cervical lymph nodes [3,
4]; secondly, it provides accurate tumor staging to facilitate
accurate prognosis and adjuvant therapy [6]; lastly, the long-
term morbidity of CCD in primary setting in experienced
hands is comparable with total thyroidectomy alone [5, 9]
and even though if it is higher [10, 26], it is still lower
than the morbidity of central compartment lymph nodes
dissection (CCD) done in reoperative setting [27]. Roh et al.
[28], in their prospective series of 45 patients with recurrent
PTC detected 86.7% recurrences in central compartment,
with high rates of temporary and permanent complications
with reoperation. There are few reports documenting no
increased risk of complications following reoperative surgeryJournal of Thyroid Research 5
comparedtoCCDdoneinprimarysetting[29–31];however,
there was also no beneﬁt of reoperative surgery as well. The
concern, whether we should remove the ipsilateral central
compartmentlymphnodesbasedonobvioustumorlocation
is also being studied by many investigators, [9, 12–14] and is
also controversial. Sadowski et al. [9] in their study reported
a mean tumor size of 1.26cm, 25.5% rate of contralateral
CCM. Similarly Roh et al. [32], in their prospective series of
52 cases with lateral LNM, had 8.9% of contralateral CCM.
Likewise, Ito et al. [33], reported 27.3% of contralateral
paratracheal lymph node metastasis, the frequency of which
was low for tumors ≤1cm (9.8%), but increased with tumor
size. They also reported signiﬁcantly decreased DFS due to
contralateral paratracheal LNM on univariate analysis. Koo
et al. [34] reported 6.7% contralateral CCM with unilateral
PTC, the rate of which was signiﬁcantly increased with
maximum tumor diameter >1cm, lymphovascular invasion
and ipsilateral lymph nodes metastasis. In their other
study [35], they found 34.3% of occult contralateral lymph
nodes involvement with unilateral lymph nodes metastasis
in lateral neck, which on multivariate analysis was found
to be signiﬁcantly associated with multifocality, ipsilateral
CCM, and lateral LNM. The rate of micrometastasis to
ipsilateral lateral lymph nodes also increases with tumor
size, and its prophylactic dissection has been recommended
by some along with ipsilateral CCD [16]; however, it is
still not recommended [8] because those compartments
are not violated during thyroidectomy, and, therefore, their
surgery at a later date will not pose for increased risk of
complications.
Thesensitivityofpreoperativeultrasound(US)indetect-
ing pathological cervical lymph nodes is 62% with the
sensitivity lower for cervical lymph nodes than for lateral
lymphnodes(55%versus65%)[36],andishigherforcentral
compartment lymph nodes following thyroidectomy than
with thyroid (90.4% versus 83.5%) [37]. Therefore, it is not
a reliable indicator of node negativity and treatmentdecision
cannot be based solely on it.
In our study, for a mean primary tumor size of 3.57 ±
2.42cm, 59.6% of the patients had central cervical lymph
nodes metastasis, which agrees with other studies. Unlike
Gimm et al. [3], in our series, the majority of the metastasis
(60.72%) involved bilateral central cervical lymphnodes
followed by isolated ipsilateral central cervical lymph nodes
(32.14%).3/29(10.34%)caseswithapparentlynodenegative
disease were found to have central compartment lymph
nodes metastasis was present on ﬁnal histopathology. Sim-
ilarly for the thyroid, out of 42 cases with apparently solitary
thyroidnoduleconﬁnedtoonelobe,8(19.5%)werefoundto
bebilateraland16(38.1%)weremulticentric.Kooetal.[38],
found 16.7% cases with occult contralateral PTC with appar-
ently unilateral papillary microcarcinoma; those cases were
missed on preoperative imaging due to their small size. Vari-
ous risk factors for central compartment lymph node metas-
tasis were analyzed by investigators with variable results [39–
41]. Majority found a signiﬁcant association of lymph nodes
metastasis with tumour size and multicentricity [33–35],
other factors being age, gender, extracapsular invasion vas-
cularinvasion,andlymphovascularinvasion.Wedidﬁndthe
tumour size a signiﬁcant predictor of central cervical lymph
nodes metastasis, and ipsilateral central cervical lymph
nodes metastasis, whereas multicentricity and ipsilateral
central lymph nodes metastasis were signiﬁcant predictors of
contralateral central cervical lymph nodes metastasis. Koo et
al. [34, 35] also had similar observations, which imply that,
for a primary tumor, apparently conﬁned to one lobe, but
with ipsilateral central or lateral metastatic lymph nodes, the
risk of contralateral central lymph nodes metastasis is pro-
portionately high and their removal is required for complete
disease clearance. Regarding size of the tumour, though the
riskoflymphnodemetastasisincreaseswithtumoursize,the
papillary microcarcinoma (PMC) was not exempt of lymph
nodal metastasis in our series. We had 5 out of 8 (62.5%)
cases with PMC, presented with lateral LNM, in which 3 had
associated CCM and 2 cases had skip metastasis, which is
contrary to the studies which consider PMC as an indolent
disease with low risk for nodal metastasis [42]. It may
probably be answered by molecular mutations analysis [43].
Many investigators advocate the use of adjuvant radioac-
tive iodine ablation as an option to take care of residual
microscopic disease; however, it has drawbacks of compli-
cations and patient’s discomfort, and also it may not be
readily available at many centres like in India, or may be
contraindicated, like in children [44], or may be legally
restricted like in Japan. Also the literature does not support
its role to decrease the locoregional recurrence, compared to
surgery[44,45].Ex c ellentpr ognosishasbeenr eport edb yI t o
et al. [25], in low-risk PTC who underwent thyroidectomy
with elective bilateral clearance of central lymph nodes
without radioactive iodine therapy.
Like other studies [9, 21], though we had higher rate
of inadvertent parathyroidectomy, temporary hypocalcemia,
and RLN palsy (P = 0.000) in patients who underwent
central lymph nodes dissection compared to total thyroidec-
tomyalone,thelong-termcomplicationswerecomparablein
boththegroups.Theriskofreoperativesurgeryistechnically
always challenging and associated with higher morbidity
[29–31], with no beneﬁt over surgery done in primary
setting.IncountrieslikeIndia,wheretheresourcesarescarce,
patients are not medically insured, radioactive iodine is not
readily available, and the regular followups are diﬃcult, it
is hard to motivate the patients for redo surgeries, rather
patients are more inclined for complete disease removal in
primary setting itself.
The strong factors with our study is its prospective
well-controlled design, which eliminates as much biases as
possible;however,likeanystudies,ithaslimitationsduetoits
small sample size, shorter followups and the nonrandomized
nature for comparing the morbidity. But on comparing with
other prospective studies, we have included considerably
morenumberofpatientsperyear,andwehopetobringmore
robust data in coming years.
5. Conclusion
The rate of central compartment lymph node metastasis is
high in PTC. Tumour size is an important risk factor for
CCM. Multicentricity and ipsilateral lymph node metastasis6 Journal of Thyroid Research
are risk factors for contralateral CCM. Bilateral CCM is
most frequent rather than ipsilateral CCM. The long-term
morbidity of bilateral CCD done in primary setting is
comparable with total thyroidectomy alone, and is safe in the
hands of experienced endocrine surgeons.
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